JP5656634B2 - タンパク質チロシンキナーゼ活性の阻害剤 - Google Patents

タンパク質チロシンキナーゼ活性の阻害剤 Download PDF

Info

Publication number
JP5656634B2
JP5656634B2 JP2010522149A JP2010522149A JP5656634B2 JP 5656634 B2 JP5656634 B2 JP 5656634B2 JP 2010522149 A JP2010522149 A JP 2010522149A JP 2010522149 A JP2010522149 A JP 2010522149A JP 5656634 B2 JP5656634 B2 JP 5656634B2
Authority
JP
Japan
Prior art keywords
alkyl
group
optionally substituted
compound
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010522149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010536887A5 (enExample
JP2010536887A (ja
Inventor
ウィリアム クラリッジ，ステファン
ウィリアム クラリッジ，ステファン
イサコヴィック，リュボミール
マニオン，マイケル
ラエペル，ステファン
マリオ サーヴェドラ，オスカー
マリオ サーヴェドラ，オスカー
ゴーデット，フレデリック
ジャン，リジエ
ゼット． ジョウ，ナンシー
ゼット． ジョウ，ナンシー
ラエペル，フランク
デジール，ロベール
ヴァイスバーグ，アルカディー
哲之 宇野
哲之 宇野
Original Assignee
メチルジーン インコーポレイテッド
メチルジーン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メチルジーン インコーポレイテッド, メチルジーン インコーポレイテッド filed Critical メチルジーン インコーポレイテッド
Publication of JP2010536887A publication Critical patent/JP2010536887A/ja
Publication of JP2010536887A5 publication Critical patent/JP2010536887A5/ja
Application granted granted Critical
Publication of JP5656634B2 publication Critical patent/JP5656634B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
JP2010522149A 2007-08-29 2008-08-28 タンパク質チロシンキナーゼ活性の阻害剤 Active JP5656634B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96867307P 2007-08-29 2007-08-29
US60/968,673 2007-08-29
PCT/CA2008/001538 WO2009026717A1 (en) 2007-08-29 2008-08-28 Inhibitors of protein tyrosine kinase activity

Publications (3)

Publication Number Publication Date
JP2010536887A JP2010536887A (ja) 2010-12-02
JP2010536887A5 JP2010536887A5 (enExample) 2011-10-13
JP5656634B2 true JP5656634B2 (ja) 2015-01-21

Family

ID=40386626

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010522149A Active JP5656634B2 (ja) 2007-08-29 2008-08-28 タンパク質チロシンキナーゼ活性の阻害剤

Country Status (19)

Country Link
US (3) US8404846B2 (enExample)
EP (1) EP2183254B1 (enExample)
JP (1) JP5656634B2 (enExample)
KR (1) KR101556269B1 (enExample)
CN (3) CN109970759A (enExample)
AR (1) AR068066A1 (enExample)
AU (1) AU2008293038B2 (enExample)
BR (1) BRPI0816064B8 (enExample)
CA (1) CA2697795C (enExample)
DK (1) DK2183254T3 (enExample)
ES (1) ES2635131T3 (enExample)
IL (1) IL204192A (enExample)
MX (1) MX2010002427A (enExample)
MY (1) MY156536A (enExample)
PL (1) PL2183254T3 (enExample)
RU (1) RU2495044C2 (enExample)
TW (1) TWI571468B (enExample)
WO (1) WO2009026717A1 (enExample)
ZA (1) ZA201001512B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009109035A1 (en) * 2008-03-05 2009-09-11 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
CA2740746A1 (en) * 2008-10-14 2010-04-22 Ning Xi Compounds comprising a spiro-ring and and methods of use
EP2408300B1 (en) * 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
US8614234B2 (en) * 2009-09-03 2013-12-24 Allergan, Inc. Compounds as tyrosine kinase modulators
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
PH12012502073A1 (en) * 2010-04-16 2013-02-11 Methylgene Inc Inhibitors of protein tyrosine kinase activity
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
JP2013532627A (ja) 2010-07-01 2013-08-19 武田薬品工業株式会社 ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ
DK2621481T4 (da) 2010-09-27 2023-01-09 Exelixis Inc Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser
JP2013540759A (ja) * 2010-09-27 2013-11-07 エクセリクシス， インク． 去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
CN103391773A (zh) * 2010-09-27 2013-11-13 埃克塞里艾克西斯公司 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
CN102827186A (zh) * 2011-06-16 2012-12-19 中国科学院上海药物研究所 一类吡啶并五元杂环衍生物及其制备方法和用途
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
WO2013166296A1 (en) 2012-05-02 2013-11-07 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
CN103626761B (zh) * 2012-08-24 2015-07-29 上海医药工业研究院 苯并吡啶氮杂卓类化合物及其作为抗肿瘤药物的应用
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201314452D0 (en) 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
KR102595599B1 (ko) 2014-12-02 2023-11-02 이그니타, 인코포레이티드 신경모세포종의 치료를 위한 병용
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction
CN108697661A (zh) 2015-12-18 2018-10-23 亚尼塔公司 用于治疗癌症的组合
CN108530464B (zh) * 2017-03-02 2020-10-27 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂
EP3654952A1 (en) 2017-07-19 2020-05-27 Ignyta, Inc. Pharmaceutical compositions comprising entrectinib
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
JP7311498B2 (ja) 2017-10-17 2023-07-19 イグナイタ インコーポレイテッド 薬学的組成物および剤形
ES2980476T3 (es) 2018-03-08 2024-10-01 Wellmarker Bio Co Ltd Derivados de tienopiridina y composición farmacéutica que los contiene
MX2020012567A (es) 2018-05-23 2021-01-29 Beigene Ltd Anticuerpos anti-ox40 y metodos de uso.
CN109384799B (zh) * 2018-11-12 2020-07-14 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂化合物的晶型a及制备方法和含有其的药物组合物
WO2021045279A1 (ko) 2019-09-06 2021-03-11 웰마커바이오 주식회사 바이오마커 기반 치료용 조성물
EP4027999B1 (en) 2019-09-10 2026-03-04 Mirati Therapeutics, Inc. Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
CN114728063B (zh) * 2019-11-21 2024-06-14 百济神州有限公司 用抗ox40抗体和多重激酶抑制剂治疗癌症
EP4089095A4 (en) * 2020-01-07 2024-03-27 Medshine Discovery Inc. DEUTERATED THIENOPYRIDINE COMPOUND
EP4213844A4 (en) 2020-09-17 2024-11-20 Mirati Therapeutics, Inc. POLYTHERAPIES
TW202302597A (zh) * 2021-03-10 2023-01-16 美商米拉蒂醫療公司 多重酪胺酸激酶抑制劑之結晶鹽、其製備方法及用途
WO2022240802A1 (en) 2021-05-10 2022-11-17 Teva Pharmaceuticals International Gmbh Solid state forms of sitravatinib salts and processes for preparation thereof
WO2023155777A1 (en) * 2022-02-15 2023-08-24 Beigene (Suzhou) Co., Ltd. N- [ (6-bromopyridin-3-yl) methyl] -2-methoxyethan-1-amine salts and preparation thereof
CN118846073B (zh) * 2024-06-25 2026-01-30 深圳海王医药科技研究院有限公司 一种酪氨酸激酶抑制剂的新应用
CN121281693B (zh) * 2025-12-08 2026-04-03 中国石油大学(华东) 一种构建稠油重组分平均分子结构的方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019A (en) * 1850-01-15 Improvement in obstetrical supporters
US7000A (en) * 1850-01-08 Smut-machine
WO1997017329A1 (en) 1995-11-07 1997-05-15 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
EP1415987B1 (en) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
DE60208364T2 (de) 2001-04-27 2006-09-28 Kirin Beer K.K. Chinolinderivate mit einer azolylgruppe und chinazolinderivate
CA2454538A1 (en) 2001-06-22 2003-01-03 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
WO2003049685A2 (en) * 2001-12-07 2003-06-19 The Regents Of The University Of California Treatment for age-related macular degeneration
UA77303C2 (en) * 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
CA2744997A1 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
EP1719762B1 (en) 2004-02-27 2012-06-27 Eisai R&D Management Co., Ltd. Novel pyridine derivative and pyrimidine derivative (1)
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
MXPA06010542A (es) * 2004-03-15 2007-03-28 Ptc Therapeutics Inc Derivados de carbolina tetra-ciclica para la inhibicion de angiogenesis.
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
CA2573538C (en) * 2004-07-30 2014-11-25 Methylgene Inc. Inhibitors of vegf receptor and hgf receptor signaling
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
JP5148499B2 (ja) * 2005-05-20 2013-02-20 メチルジーン インコーポレイテッド Ｖｅｇｆ受容体およびｈｇｆ受容体シグナル伝達の阻害剤
ES2473341T3 (es) 2005-05-20 2014-07-04 Methylgene Inc Inhibidores de la se�alizaci�n del receptor del VEGF y del receptor del HGF
TW200740820A (en) 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
PL1889836T3 (pl) 2005-08-24 2013-10-31 Eisai R&D Man Co Ltd Nowa pochodna pirydyny i pochodna pirymidyny (3)
AR059246A1 (es) * 2006-01-30 2008-03-19 Array Biopharma Inc Compuestos heterobiciclicos de tiofeno y metodos de uso
MX2008011220A (es) 2006-03-07 2008-09-11 Array Biopharma Inc Compuestos de pirazol heterobiciclicos y metodos de uso.
WO2007107005A1 (en) * 2006-03-22 2007-09-27 Methylgene, Inc. Inhibitors of protein tyrosine kinase activity
US20110053931A1 (en) 2006-06-08 2011-03-03 John Gaudino Quinoline compounds and methods of use
WO2008049855A2 (en) 2006-10-27 2008-05-02 Glaxo Group Limited 7-azaindole derivatives as c-met kinase inhibitors
PH12012502073A1 (en) * 2010-04-16 2013-02-11 Methylgene Inc Inhibitors of protein tyrosine kinase activity

Also Published As

Publication number Publication date
CN101932586A (zh) 2010-12-29
CA2697795C (en) 2016-08-16
CN105777776B (zh) 2021-06-08
MX2010002427A (es) 2010-03-30
US20120108628A1 (en) 2012-05-03
CA2697795A1 (en) 2009-03-05
EP2183254B1 (en) 2017-06-21
EP2183254A1 (en) 2010-05-12
KR101556269B1 (ko) 2015-09-30
US8404846B2 (en) 2013-03-26
ZA201001512B (en) 2010-11-24
MY156536A (en) 2016-02-26
JP2010536887A (ja) 2010-12-02
KR20100075873A (ko) 2010-07-05
BRPI0816064A2 (pt) 2015-03-31
ES2635131T3 (es) 2017-10-02
US8846927B2 (en) 2014-09-30
CN109970759A (zh) 2019-07-05
PL2183254T3 (pl) 2017-10-31
AU2008293038B2 (en) 2013-08-29
RU2010111729A (ru) 2011-10-10
CN105777776A (zh) 2016-07-20
BRPI0816064B8 (pt) 2021-05-25
US20130165477A1 (en) 2013-06-27
US8389541B2 (en) 2013-03-05
TWI571468B (zh) 2017-02-21
AU2008293038A1 (en) 2009-03-05
DK2183254T3 (en) 2017-09-11
EP2183254A4 (en) 2011-09-28
BRPI0816064B1 (pt) 2020-01-28
TW200914458A (en) 2009-04-01
IL204192A (en) 2016-08-31
RU2495044C2 (ru) 2013-10-10
US20090264440A1 (en) 2009-10-22
WO2009026717A1 (en) 2009-03-05
AR068066A1 (es) 2009-11-04

Similar Documents

Publication Publication Date Title
JP2010536887A (ja) タンパク質チロシンキナーゼ活性の阻害剤
JP5661485B2 (ja) タンパク質チロシンキナーゼ活性の阻害剤
TW201329085A (zh) 蛋白酪氨酸激酶活性抑制劑
TW201329086A (zh) 蛋白酪氨酸激酶活性抑制劑
HK1139407B (en) Inhibitors of protein tyrosine kinase activity
HK1139407A (en) Inhibitors of protein tyrosine kinase activity
HK1155977A (en) Inhibitors of protein tyrosine kinase activity

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20101222

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20110217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110826

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130716

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131106

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131118

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141003

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141125

R150 Certificate of patent or registration of utility model

Ref document number: 5656634

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250